PE20020253A1 - 3-AZABICYCLE DERIVATIVES [3.1.0] HEXANE AS LIGANDS OF OPIACEAN RECEPTORS - Google Patents
3-AZABICYCLE DERIVATIVES [3.1.0] HEXANE AS LIGANDS OF OPIACEAN RECEPTORSInfo
- Publication number
- PE20020253A1 PE20020253A1 PE2001000604A PE2001000604A PE20020253A1 PE 20020253 A1 PE20020253 A1 PE 20020253A1 PE 2001000604 A PE2001000604 A PE 2001000604A PE 2001000604 A PE2001000604 A PE 2001000604A PE 20020253 A1 PE20020253 A1 PE 20020253A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ethyl
- hexane
- derivatives
- halo
- Prior art date
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000005228 3‐azabicyclo[3.1.0]hexanes Chemical class 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS 3-AZABICICLO[3.1.0]HEXANO DE FORMULA I DONDE Ar ES FENILO OPCIONALMENTE CONDENSADO CON BENCENO O UN ANILLO HETEROARILO DE 5 A 6 MIEMBROS; R1 ES H, HALO, NO2, NH2, NY2WY1, HET, AD, OE, ENTRE OTROS; Y2 ES H, ALQUILO C1-C6, ALQUENILO C3-C6, ENTRE OTROS; W ES SO2, CO, C(O)O, P(Y1)=S, ENTRE OTROS; Y1 ES ALQUILO C1-C10 CON HALOGENO, OH, ALCOXI C1-C4, ALCANOILOXI C1-C6, ENTRE OTROS; HET ES HETEROCICLICO CON 4 HETEROATOMOS SELECCIONADOS DE N, O, S QUE PUEDE COMPRENDER HASTA 3 ANILLOS SUSTITUIDOS CON ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; A ES ALQUILENO C1-C4, ALQUENILENO C2-C4, ALQUINILENO C2-C4 CON ALQUILO C1-C4, ALCOXI C1-C4, HALOGENO, OH; D ES H, OH, CN, ENTRE OTROS; E ES H, CONR23R23, ENTRE OTROS. R23 ES H, ALQUILO C1-C4, HALOALQUILO C1-C4; R2 ES H, HALO; R3 ES H, CN, HALO; R4 ES ALQUILO C1-C10, ALQUENILO; R5 Y R8 SON H, ALQUILO C1-C6; R6, R7, R9 Y R10 SON H; n ES 0-2; q ES 0-1. SON COMPUESTOS PREFERIDOS N-(3-{6-ETIL-3-[2-(2-HIDROXIETOXI)-ETIL]-3-AZABICICLO-[3.1.0]HEX-6-IL}-FENIL)METANOSULFONAMIDA, N-(3-{3-{2-[2-(DIMETILAMINO)ETOXI)-ETIL]-6-ETIL-3-AZABICICLO-[3.1.0]HEX-6-IL}-FENIL)METANOSULFONAMIDA, ENTRE OTROS. LOS DERIVADOS DE 3-AZABICICLO[3.1.0]HEXANO SON LIGANDOS DE RECEPTORES OPIACEOS Y SON UTILES PARA EL TRATAMIENTO DEL SINDROME DEL INTESTINO IRRITABLE, ESTRENIMIENTO, NAUSEAS, VOMITOSREFERS TO 3-AZABYCYCLE [3.1.0] HEXANE DERIVATIVES OF FORMULA I WHERE Ar IS PHENYL OPTIONALLY CONDENSED WITH BENZENE OR A 5 TO 6 MEMBER HETEROARYL RING; R1 IS H, HALO, NO2, NH2, NY2WY1, HET, AD, OE, AMONG OTHERS; Y2 IS H, C1-C6 ALKYL, C3-C6 ALKYL, AMONG OTHERS; W IS SO2, CO, C (O) O, P (Y1) = S, AMONG OTHERS; Y1 IS C1-C10 ALKYL WITH HALOGEN, OH, C1-C4 ALCOXY, C1-C6 ALKANOYLOXY, AMONG OTHERS; HET IS HETEROCYCLIC WITH 4 HETEROATOMS SELECTED FROM N, O, S WHICH CAN INCLUDE UP TO 3 RINGS REPLACED WITH C1-C6 ALKYL, C1-C6 ALCOXI, AMONG OTHERS; A IS C1-C4 ALKYLENE, C2-C4 ALKYLENE, C2-C4 ALKYLENE WITH C1-C4 ALKYL, C1-C4 ALCOXY, HALOGEN, OH; D IS H, OH, CN, AMONG OTHERS; E IS H, CONR23R23, AMONG OTHERS. R23 IS H, C1-C4 ALKYL, C1-C4 HALOALKYL; R2 IS H, HALO; R3 IS H, CN, HALO; R4 IS C1-C10 ALKYL, ALKENYL; R5 AND R8 ARE H, C1-C6 ALKYL; R6, R7, R9 AND R10 ARE H; n IS 0-2; q IS 0-1. PREFERRED COMPOUNDS ARE N- (3- {6-ETHYL-3- [2- (2-HYDROXYETOXY) -ETHYL] -3-AZABICYCLO- [3.1.0] HEX-6-IL} -PHENYL) METHANOSULFONAMIDE, N- ( 3- {3- {2- [2- (DIMETHYLAMINO) ETHOXY) -ETHYL] -6-ETHYL-3-AZABICYCLE- [3.1.0] HEX-6-IL} -PHENYL) METHANOSULFONAMIDE, AMONG OTHERS. THE DERIVATIVES OF 3-AZABICYCLO [3.1.0] HEXANE ARE BINDERS OF OPIOUS RECEPTORS AND ARE USEFUL FOR THE TREATMENT OF THE SYNDROME OF THE IRRITABLE INTESTINE, STRENGTH, NAUSEA, VOMITING
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015562.2A GB0015562D0 (en) | 2000-06-23 | 2000-06-23 | Heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020253A1 true PE20020253A1 (en) | 2002-04-08 |
Family
ID=9894368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000604A PE20020253A1 (en) | 2000-06-23 | 2001-06-21 | 3-AZABICYCLE DERIVATIVES [3.1.0] HEXANE AS LIGANDS OF OPIACEAN RECEPTORS |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1292574A1 (en) |
| JP (1) | JP2004512263A (en) |
| KR (1) | KR20040002386A (en) |
| CN (1) | CN1639121A (en) |
| AP (1) | AP2002002698A0 (en) |
| AR (1) | AR028969A1 (en) |
| AU (1) | AU781837B2 (en) |
| BG (1) | BG107329A (en) |
| BR (1) | BR0111867A (en) |
| CA (1) | CA2412188A1 (en) |
| CZ (1) | CZ20023967A3 (en) |
| DO (1) | DOP2001000187A (en) |
| DZ (1) | DZ3368A1 (en) |
| EA (1) | EA005117B1 (en) |
| GB (1) | GB0015562D0 (en) |
| HR (1) | HRP20020998A2 (en) |
| HU (1) | HUP0301228A3 (en) |
| IL (1) | IL153427A0 (en) |
| IS (1) | IS6637A (en) |
| MA (1) | MA26915A1 (en) |
| MX (1) | MXPA02012878A (en) |
| NO (1) | NO20026168L (en) |
| NZ (1) | NZ523141A (en) |
| OA (1) | OA12293A (en) |
| PA (1) | PA8519401A1 (en) |
| PE (1) | PE20020253A1 (en) |
| PL (1) | PL365956A1 (en) |
| SK (1) | SK17172002A3 (en) |
| TN (1) | TNSN01094A1 (en) |
| UA (1) | UA73176C2 (en) |
| UY (1) | UY26787A1 (en) |
| WO (1) | WO2001098267A1 (en) |
| YU (1) | YU91802A (en) |
| ZA (1) | ZA200210278B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0213464A (en) * | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | 3-Azabicyclo [3.1.0] hexane derivatives as opioid receptor antagonists |
| DK1505974T3 (en) * | 2002-05-17 | 2009-08-17 | Tioga Pharmaceuticals Inc | Use of compounds that are effective as selective opiate receptor modulators |
| DE10259245A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivatives of asimadolin with covalently bound acids |
| CN1946714B (en) * | 2004-02-23 | 2011-06-15 | 葛兰素集团有限公司 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| GB0507680D0 (en) | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| US7807698B2 (en) | 2005-06-14 | 2010-10-05 | Glaxo Group Limited | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor |
| WO2007113258A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| ES2393815T3 (en) | 2007-03-30 | 2012-12-28 | Tioga Pharmaceuticals, Inc. | Kappa opioid agonists for the treatment of irritable bowel syndrome with predominant and alternating diarrhea |
| TWI423801B (en) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists |
| JP5736040B2 (en) | 2010-06-11 | 2015-06-17 | ローズ テクノロジーズ | Transition metal catalyzed process and its use for the preparation of N-allyl compounds |
| BR112013007566A2 (en) | 2010-09-28 | 2016-08-02 | Panacea Biotec Ltd | new bicyclic compounds |
| WO2015076310A1 (en) * | 2013-11-20 | 2015-05-28 | 株式会社 三和化学研究所 | Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes |
| MX388953B (en) | 2015-05-20 | 2025-03-20 | Ube Industries | NOVEL 3-AZABICICLO[3.1.0]HEXANE DERIVATIVE SALT CRYSTAL AND MEDICATIONAL USES THEREOF. |
| WO2018152286A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| KR20190129867A (en) * | 2017-02-17 | 2019-11-20 | 트레베나, 인코포레이티드. | 5-membered aza-heterocycle-containing delta-opioid receptor modulating compounds, and methods of using and preparing the same |
| KR20190120212A (en) | 2017-03-02 | 2019-10-23 | 가부시키가이샤산와카가쿠켄큐쇼 | Drug of alcohol use disorder |
| CN108250088B (en) * | 2018-01-04 | 2020-10-30 | 四川之江高新材料股份有限公司 | The preparation method of N,N,N'-trimethyl-N'-hydroxyethyl bisaminoethyl ether |
| CN115825305B (en) * | 2022-10-21 | 2024-09-20 | 昆明理工大学 | Molecularly imprinted solid-phase microextraction fiber and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065230A (en) * | 1959-03-16 | 1962-11-20 | Burroughs Wellcome Co | Azabicyclohexanes and method of preparing them |
| NZ224236A (en) * | 1987-04-16 | 1990-08-28 | Lilly Co Eli | Trans 3,4 pyridine derivatives and pharmaceutical compositions |
| US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| DE4341403A1 (en) * | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituted 3-azabicycloalkane derivatives, their preparation and use |
| TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| PE20001420A1 (en) * | 1998-12-23 | 2000-12-18 | Pfizer | CCR5 MODULATORS |
-
2000
- 2000-06-23 GB GBGB0015562.2A patent/GB0015562D0/en not_active Ceased
-
2001
- 2001-06-06 DO DO2001000187A patent/DOP2001000187A/en unknown
- 2001-06-07 BR BR0111867-6A patent/BR0111867A/en not_active IP Right Cessation
- 2001-06-07 HU HU0301228A patent/HUP0301228A3/en unknown
- 2001-06-07 AU AU62591/01A patent/AU781837B2/en not_active Ceased
- 2001-06-07 JP JP2002504223A patent/JP2004512263A/en not_active Withdrawn
- 2001-06-07 PL PL01365956A patent/PL365956A1/en not_active Application Discontinuation
- 2001-06-07 CN CNA018116086A patent/CN1639121A/en active Pending
- 2001-06-07 HR HR20020998A patent/HRP20020998A2/en not_active Application Discontinuation
- 2001-06-07 KR KR1020027017503A patent/KR20040002386A/en not_active Ceased
- 2001-06-07 CA CA002412188A patent/CA2412188A1/en not_active Abandoned
- 2001-06-07 EP EP01936728A patent/EP1292574A1/en not_active Withdrawn
- 2001-06-07 CZ CZ20023967A patent/CZ20023967A3/en unknown
- 2001-06-07 IL IL15342701A patent/IL153427A0/en unknown
- 2001-06-07 YU YU91802A patent/YU91802A/en unknown
- 2001-06-07 WO PCT/IB2001/001035 patent/WO2001098267A1/en not_active Ceased
- 2001-06-07 OA OA1200200386A patent/OA12293A/en unknown
- 2001-06-07 AP APAP/P/2002/002698A patent/AP2002002698A0/en unknown
- 2001-06-07 NZ NZ523141A patent/NZ523141A/en unknown
- 2001-06-07 SK SK1717-2002A patent/SK17172002A3/en unknown
- 2001-06-07 EA EA200201269A patent/EA005117B1/en not_active IP Right Cessation
- 2001-06-07 DZ DZ013368A patent/DZ3368A1/en active
- 2001-06-07 MX MXPA02012878A patent/MXPA02012878A/en unknown
- 2001-06-12 PA PA20018519401A patent/PA8519401A1/en unknown
- 2001-06-21 UY UY26787A patent/UY26787A1/en not_active Application Discontinuation
- 2001-06-21 PE PE2001000604A patent/PE20020253A1/en not_active Application Discontinuation
- 2001-06-21 AR ARP010102957A patent/AR028969A1/en unknown
- 2001-06-22 TN TNTNSN01094A patent/TNSN01094A1/en unknown
- 2001-07-06 UA UA20021210406A patent/UA73176C2/en unknown
-
2002
- 2002-11-28 IS IS6637A patent/IS6637A/en unknown
- 2002-11-28 BG BG107329A patent/BG107329A/en unknown
- 2002-12-16 MA MA26955A patent/MA26915A1/en unknown
- 2002-12-19 ZA ZA200210278A patent/ZA200210278B/en unknown
- 2002-12-20 NO NO20026168A patent/NO20026168L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020253A1 (en) | 3-AZABICYCLE DERIVATIVES [3.1.0] HEXANE AS LIGANDS OF OPIACEAN RECEPTORS | |
| PE20010964A1 (en) | THIAZOLILAMIDE DERIVATIVES | |
| PE20061297A1 (en) | CHROME AND CHROME DERIVED COMPOUNDS MODULATING THE SEROTONIN 5-HT2C RECEPTOR | |
| PE20061124A1 (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINE | |
| DK1173433T3 (en) | Cyanopyrrols as progesterone receptor agonists | |
| PE20030039A1 (en) | INDOLE DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEPTOR | |
| PE20050482A1 (en) | DIHYDROBENZOFURANIL ALKANAMIDE DERIVATIVES | |
| PE20061335A1 (en) | BENZODIOXANE AND BENZODIOXOLANE DERIVED COMPOUNDS AS MODULATORS OF THE 5-HT2C RECEPTOR | |
| PE20070189A1 (en) | AMINO-5-HETEROARYL COMPOUND (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR ß-SECRETASE MODULATION | |
| ATE317378T1 (en) | TRIPHENYL ALKENDER DERIVATIVES AND THEIR USE AS SELECTIVE MODULATORS OF THE ESTROGEN RECEPTOR | |
| PE20050131A1 (en) | BENZOIMIDAZOLE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | |
| PE20020753A1 (en) | HETEROAROMATICS FUSED AS GLUCOKINASE ACTIVATORS | |
| PE20020131A1 (en) | DERIVATIVES OF PIRAZOLE | |
| PE20001643A1 (en) | USE OF CRF ANTAGONISTS THAT IMPROVE QT DISPERSION AND HEART RATE VARIABILITY TO PREVENT SUDDEN DEATH | |
| PE20011212A1 (en) | COMPOUNDS FOR THE TREATMENT OF FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | |
| CO5160347A1 (en) | CARBAMIC ACID DERIVATIVES | |
| AR036906A1 (en) | IMIDAZOPIRIDIN COMPOUNDS AS 5-HT4 RECEIVER MODULATORS | |
| PE20050420A1 (en) | PHENACILO 2-HYDROXY-3-DIAMINOALKANOS | |
| NO952208D0 (en) | The amine derivatives | |
| AR038881A1 (en) | COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND A PROCEDURE FOR THE PREPARATION OF THOSE | |
| PE20020063A1 (en) | BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR | |
| DK1153017T3 (en) | Bicyclic compounds and their use as integrin receptor ligands | |
| PE20040828A1 (en) | BENZOXAZINONES AS MODULARS OF 5-HYDROXITRIPTAMINE (5-HT) | |
| AR039111A1 (en) | THIN-PYRIMIDINES AND ISOTIAZOLPIRIMIDINAS INHIBITORAS DE QUINASAS | |
| AR015964A1 (en) | ISOQUINOLINE COMPOUNDS, ITS USE, PROCEDURE TO TREAT AN AFFECTION, COMPOUND PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION THAT LOCONTIATES AND USEFUL COMPOUND IN THIS PROCEDURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |